Storia in 12 fonti

AstraZeneca shares slide 9% after heart treatment disappoints in trial

UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths

Raccontata da

cnbc.com

thehindubusinessline.com

endpoints.news

economictimes.indiatimes.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

irishtimes.comStai leggendo1 mese fa

AstraZeneca shares slide 9% after heart treatment disappoints in trial

UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths

originale

Timeline cronologica

giovedì 9 luglio 2026·cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
giovedì 9 luglio 2026·thehindubusinessline.com
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems

economictimes.indiatimes.com

1 mese fa

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug…

Leggi questa versione → originale

cnbc.com1 mese fa

AstraZeneca stock dives 9% after heart drug trial misses target

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

Leggi questa versione → originale

thehindubusinessline.com1 mese fa

AstraZeneca’s Wainua fails main goal in late-stage heart disease trial

Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems

Leggi questa versione → originale

endpoints.news1 mese fa

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

Leggi questa versione → originale

independent.co.uk1 mese fa

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

Leggi questa versione → originale

giovedì 9 luglio 2026·

endpoints.news

AstraZeneca sinks on unexpected heart drug trial failure

AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.

giovedì 9 luglio 2026·

economictimes.indiatimes.com

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer…

giovedì 9 luglio 2026·

milanofinanza.it

AstraZeneca crolla in borsa a Londra dopo il flop del farmaco Wainua: il titolo perde fino al 9% | MilanoFinanza News

Il gruppo farmaceutico britannico affonda dopo che lo studio clinico di fase avanzata sul farmaco Wainua non ha raggiunto l'obiettivo principale. Gli analisti rassicurano però…

giovedì 9 luglio 2026·

statnews.com

AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.

giovedì 9 luglio 2026·

morningstar.com

Dow Jones Top Company Headlines at 5 AM ET: AstraZeneca Says Wainua Trial Failed to Meet Primary Goal | China's ...

AstraZeneca Says Wainua Trial Failed to Meet Primary Goal

giovedì 9 luglio 2026·

independent.co.uk

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

giovedì 9 luglio 2026·

ilsole24ore.com

A Londra scivolone di Astrazeneca dopo fallimento trial Wainua per malattia cardiaca

Il farmaco ha fallito l'obiettivo di ridurre i decessi cardiovascolari e le recidive di problemi cardiaci in una sperimentazione di fase avanzata

giovedì 9 luglio 2026·

latercera.com

AstraZeneca se derrumba en bolsa tras fracaso de ensayo clínico para fármaco cardíaco - La Tercera

Wainua no cumplió su objetivo principal en un estudio de fase avanzada para una rara condición cardíaca.

giovedì 9 luglio 2026·

irishtimes.com

AstraZeneca shares slide 9% after heart treatment disappoints in trial

UK pharmaceutical company said Wainua drug did not meet goal of reducing cardiovascular deaths

giovedì 9 luglio 2026·

fiercepharma.com

AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction

The surprising failure of AstraZeneca and Ionis in a key phase 3 tria | The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with ATTR-CM…

sabato 11 luglio 2026·

cnbc.com

AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.